Meda Finds Marketer For Elestrin As It Concentrates On Respiratory
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swedish specialty pharma is devoting more resources to its growing respiratory franchise and shifting focus away from other therapeutic areas, including women’s health.
You may also be interested in...
Jazz Cools On Women’s Health, Sells Unit To Meda
The sale of an asset portfolio that includes Elsetrin for hot flashes could give Jazz the financial flexibility for another product acquisition.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.